文献速递胃肠外科围术期管理与 ERAS

新型胃肠减压管联合保守治疗用于全胃切除术后食管空肠吻合口漏的短期结局

Short-term outcomes of a new gastrointestinal decompression tube combined with conservative treatment in patients with esophagojejunal anastomotic leakage after total gastrectomy.
PubMed 文献 · Surg Endosc · 2022-10-13

该回顾性研究分析了81例全胃切除Roux-en-Y重建后发生食管空肠吻合口漏(EJAL)的患者,比较新型胃肠减压管联合保守治疗(实验组12例)与单纯保守治疗(对照组69例)的短期结局。结果显示实验组临床成功时间(16.0±8.3 vs 23.6±17.8,P=0.04)和住院时间(30.1±6.3 vs 36.8±16.7,P=0.017)显著短于对照组;当缺损≥4 mm时,实验组临床成功时间、住院时间和住院费用均低于对照组(P<0.05)。

要点

  • 新型胃肠减压管联合保守治疗可缩短EJAL临床成功时间和住院时间。
  • 缺损≥4 mm时,联合治疗还降低住院费用。
  • 对照组缺损大小与临床成功时间、住院时间和费用呈线性相关。

核心结论

  • 置入新型胃肠减压管是安全的治疗方式。
  • 当缺损≥4 mm时,可缩短临床成功时间、住院时间并降低住院费用。

研究设计与样本

  • 回顾性分析2014年1月至2021年12月福建医科大学附属协和医院81例全胃切除Roux-en-Y重建后EJAL患者。
  • 实验组12例接受新型胃肠减压管联合保守治疗,对照组69例接受单纯保守治疗。

主要发现

  • 两组吻合口缺损大小、术后缺损出现时间、住院费用和抗生素使用时间无显著差异。
  • 实验组临床成功时间显著短于对照组(16.0±8.3 vs 23.6±17.8,P=0.04)。
  • 实验组住院时间显著短于对照组(30.1±6.3 vs 36.8±16.7,P=0.017)。
  • 缺损≥4 mm时,实验组临床成功时间、住院时间和住院费用均低于对照组(P<0.05)。
  • 对照组缺损大小与临床成功时间、住院时间和住院费用呈线性相关。

关键数值与推荐

  • 缺损≥4 mm时,实验组临床成功时间、住院时间和住院费用低于对照组(P<0.05)。

临床怎么用

  • 对于全胃切除术后EJAL,可考虑置入新型胃肠减压管联合保守治疗,尤其缺损≥4 mm者可能获益。

局限性

  • 回顾性研究,实验组样本量较小(12例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To compare the short-term outcomes of a new gastrointestinal decompression tube combined with conservative treatment in patients with esophagojejunal anastomotic leakage (EJAL) after total gastrectomy. We retrospectively analyzed the data of 81 patients with EJAL who had undergone total gastrectomy and Roux-en-Y reconstruction at Fujian Medical University Union Hospital between January 2014 and December 2021. The patients were divided into experimental (12 patients with new gastrointestinal decompression tube plus conservative treatment) and control (69 patients with conservative treatment) groups, according to the different treatment methods they received. Anatomic defect size linearly correlated with time to clinical success, hospital stay, and hospital cost in the control group. The two groups showed no significant differences in anastomotic defect size, time of defect after surgery, hospitalization cost, and time of antibiotic use. However, the time to clinical success was significantly shorter in the experimental group than in the control group (16.0 ± 8.3 vs. 23.6 ± 17.8, P = 0.04), as was the length of hospital stay (30.1 ± 6.3 vs. 36.8 ± 16.7, P = 0.017). Furthermore, when the defect size was ≥ 4 mm, the time to clinical success, hospital stay, and hospital cost in the experimental group were lower than those in the control group (P < 0.05). Placement of a new gastrointestinal decompression tube is a safe treatment. When the defect size is ≥ 4 mm, the time to clinical success, length of hospital stay, and hospital cost can be reduced.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Wang SJ, Duan Q, Xue YJ, et al. Short-term outcomes of a new gastrointestinal decompression tube combined with conservative treatment in patients with esophagojejunal anastomotic leakage after total gastrectomy. Surg Endosc. 2022. PMID: 36229555. doi:10.1007/s00464-022-09694-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。